<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-153465</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Recommendations for the use of methotrexate in established rheumatoid arthritis: monotherapy and combination with other synthetic or biological DMARDs</dc:title>
<dc:description xml:lang="en">The aim of this document is to describe the optimal use of: a) methotrexate (MTX) monotherapy in established RA in readministration after a previous effective cycle, and b) MTX combination with synthetic and biological DMARD. Clinical questions were proposed and a systematic literature search was conducted. Recommendations were developed and then discussed and validated in a working session with fifteen experts. After an effective cycle, MTX will be restarted with the same dose and route of administration than previously, following an intensive strategy if the dose were insufficient or the patient had poor prognostic factors. When sustained remission, MTX may be reduced gradually, with a close monitoring of the patient. Before starting a combination therapy with other synthetic or biologic DMARD, full doses of MTX should be reached and the use of the parenteral route evaluated. In established RA, when starting the combination of MTX with a biological DMARD, the same dose and route of administration of MTX than previously used should be maintained. In patients in remission for at least 6 months and in combination therapy with a biological, it is recommended to reduce the dose of the biological agent or increase its administration period before reducing the dose of MTX, unless side effects due to MTX. This document pretends to solve some frequent clinical questions on the use of MTX in monotherapy and/or in combination therapy with other synthetic or biological DMAR (AU)</dc:description>
<dc:creator>Ballina, Francisco Javier</dc:creator>
<dc:creator>Tornero Molina, Jesús</dc:creator>
<dc:creator>Calvo Alén, Jaime</dc:creator>
<dc:creator>Sanmartí, Raimon</dc:creator>
<dc:creator>Rosas, José</dc:creator>
<dc:creator>Miguélez, Juan Roberto</dc:creator>
<dc:creator>Quijada, Jesús</dc:creator>
<dc:creator>Corominas, Héctor</dc:creator>
<dc:creator>Nolla, Joan M</dc:creator>
<dc:creator>Castañeda, Santos</dc:creator>
<dc:creator>Carbonell, Jordi</dc:creator>
<dc:creator>Blanco, Francisco J</dc:creator>
<dc:creator>Caracuel, Miguel Ángel</dc:creator>
<dc:creator>Moreno, José Vicente</dc:creator>
<dc:creator>Pérez, Trinidad</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El metotrexato, utilizado a dosis bajas semanales, es actualmente el tratamiento de referencia en la artritis reumatoide. No se conoce con exactitud el mecanismo de acción en esta enfermedad, pero se han descrito diversas acciones antiproliferativas, antiinflamatorias e inmunorreguladoras que pueden contribuir a su efecto terapéutico. Diversos ensayos clínicos demostraron en la década de los ochenta del siglo pasado su eficacia clínica, así como su efecto enlentecedor del daño anatómico. En los últimos años se ha visto además que llegar a dosis más altas de las inicialmente utilizadas, entre 25 y 30 mg/semanales, puede maximizar sus efectos. En pacientes resistentes, el metotrexato también puede ser útil en terapia combinada con otros fármacos modificadores de la enfermedad, sintéticos o biológicos. Habitualmente, el metotrexato es bien tolerado, pero puede tener efectos adversos a diversos niveles (hematológico, digestivo, hepático, neurológico o pulmonar), alguno de los cuales pueden ser graves, por lo que requiere una cuidadosa monitorización clínica y analítica (AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);11(supl.1): 29-35, ene. 2016. tab</dc:source>
<dc:identifier>ibc-153465</dc:identifier>
<dc:title xml:lang="es">Recomendaciones para el uso de metotrexato en artritis reumatoide establecida: monoterapia y combinación con otros fármacos modificadores de la enfermedad sintéticos o biológicos</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d28621</dc:subject>
<dc:subject>^d50071</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d22870</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d4419^s22074</dc:subject>
<dc:subject>^d4419^s22045</dc:subject>
<dc:subject>^d28169^s22073</dc:subject>
<dc:subject>^d32355^s22044</dc:subject>
<dc:subject>^d1178^s22057</dc:subject>
<dc:subject>^d32355^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201601</dc:date>
</metadata>
</record>
</ibecs-document>
